Biotricity, Inc. - Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)		3 Months Ended		6 Months Ended
		Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement
Revenue		$ 84,760		$ 102,420
Cost of revenue		47,118		56,918
Net revenue		37,642		45,502
Expenses:
General and administrative expenses	[1]	2,026,523	$ 1,041,275	4,154,829	$ 2,129,474
Research and development expenses		187,859	413,624	487,930	728,734
Total Operating Expenses		2,214,382	1,454,899	4,642,759	2,858,208
Accretion expense	[2]				879,416
Change in fair value of derivative liabilities	[3]				20,588
Net loss before income taxes		(2,176,740)	(1,454,899)	(4,597,257)	(3,758,212)
Income taxes
Net loss		(2,176,740)	(1,454,899)	(4,597,257)	(3,758,212)
Translation adjustment		112,866	(83,858)	10,217	(170,348)
Comprehensive loss		$ (2,063,874)	$ (1,538,757)	$ (4,587,040)	$ (3,928,560)
Loss per share, basic and diluted		$ (0.066)	$ (0.048)	$ (0.142)	$ (0.127)
Weighted average number of common shares outstanding		32,819,848	30,590,667	32,377,274	29,529,534

[1] See Notes 7, 8 and 9

[2] See Note 5

[3] See Note 6